PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Ciclosporin - Inflammatory bowel disease

PAD Profile : Ciclosporin - Inflammatory bowel disease Important

Keywords :
IBD, severe ulcerative colitis
Brand Names Include :
Capimune, Capsorin, Deximune, Neoral, Sandimmun, Vanquoral
Important Information :
Ulcerative colitis only. Prescribe by brand

Traffic Light Status

Status 1 of 2.

Status :
Red
Formulations :
  • Capsules
  • Intravenous infusion
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Status 2 of 2.

Status :
Red
Important
Formulations :
  • Oral solution
Important Information :
Ulcerative colitis only
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
BNF NICE SPC
Un
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
02 August 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed a local adaptation of the National Shared Care document, in reference to the routine monitoring of CRP (rather than ESR) in primary care for inflammatory indications

02 November 2022
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands integrated care system Area Prescribing Committee (APC) approve the RMOC national shared care protocol with ‘local adaptations’.

This shared care protocol applies to adults aged 18 and over.

The local adaptation excludes gastroenterology indications from shared care, as it is considered a short-term treatment requiring hospital led treatment, and therefore a RED traffic light status, and this is endorsed by the Surrey Heartlands clinicians. All other indications listed in the shared care document will be considered AMBER

This shared care protocol also includes treatment of chronic inflammatory conditions where off-label use of ciclosporin is appropriate, including, but not limited to, the specialities and conditions described in Section 3 of the document.

These indications are off-label. The specialist must specify the indication for each patient when initiating shared care and clearly state when use is off-label.

06 May 2015
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
The PCN recommend the use of Infliximab, Adalimumab and Golimumab in line with NICE TA329 and a treatment pathway is attached which has been developed with local specialists. Aminosalicylates and Thiopurines are included in the pathway as treatment options.
28 August 2013
Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
It was noted that ciclosporin is only used in a small number of IBD patients and that these patients are generally very unwell and therefore are regularly reviewed by secondary care. It was noted that ciclosporin is usually only given for 3-6 months and is not ongoing in this patient cohort. During this time period they are monitored closely by secondary care. It was therefore felt that it would be inappropriate to have a shared care for ciclosporin for IBD.

Associated BNF Codes

01. Gastro-Intestinal System
01.05.03. Drugs affecting immune response
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More